Radiometals as payloads for radioimmunotherapy for lymphoma

Clinical Lymphoma

Volumn 5, Issue SUPPL. 1, 2004, Pages

  DeNardo, Gerald L ^a,d   Kennel, Stephen J ^b   Siegel, Jeffry A ^c   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OAK RIDGE NATIONAL LABORATORY   (United States)

^c Nuclear Physics Enterprises   (United States)

^d Molecular Cancer Institute   (United States)

Author keywords

131I tositumomab; 90Y Ibritumomab tiuxetan; Monoclonal atibodies; Radionuclide

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM; BISMUTH 213; CD20 ANTIBODY; COPPER 64; COPPER 67; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 123; IODINE 125; IODINE 131; LANTHANIDE; LUTETIUM; PENTETIC ACID DERIVATIVE; RADIOISOTOPE; RADIUM; RHENIUM 186; RHENIUM 188; RITUXIMAB; STREPTAVIDIN; TOSITUMOMAB I 131; YTTRIUM 90;

ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ECONOMIC ASPECT; ENDOCYTOSIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; IODINATION; ISOTOPE LABELING; LYMPHOMA; LYMPHOMA CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PHYSICAL CHEMISTRY; RADIOIMMUNOTHERAPY; SIDE EFFECT; TARGET CELL;

EID: 7744231440     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.s.002     Document Type: Article

References (58)

1. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiophar 1988; 1: 17-33.
2. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers 1987; 2:49-53.
3. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998; 16:3246-3256.
4. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992; 10: 1696-1711.
5. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989; 7:1027-1038.
6. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346:336-340.
7. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-1266.
8. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19:3918-3928.
9. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995; 55:5899s-5907s.
10. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin Cancer Res 1999; 5:3292s-3303s.
11. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996; 56:2123-2129.
12. 111In-labeled monoclonal antitumor antibodies in normal animals and nude-mouse human tumor models. Cancer Res 1983; 43:5347-5355.
13. Michel RB, Ochakovskaya R, Mattes MJ. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: Importance of using residualizing radiolabels. Clin Cancer Res 2002; 8:2632-2639.
14. Leichner PK, Yang NC, Frenkel TL, et al. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys 1988; 14:1033-1042.
15. Parker BA, Vassos AB, Halpern SE, et al. Radioimmunotherapy of human B-cell lymphoma with Y-90-conjugated antiidiotype monoclonal antibody. Cancer Res 1990; 50(suppl):1022s-1028s.
16. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 2000; 15:15-29.
17. Weiden PL, Breitz HB. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol 2001; 40:37-51.
18. 131I-labeled Lym-1 antibody: Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5:533-541.
19. 131I. J Nucl Med 2001; 42:967-974.
20. DeNardo GL, DeNardo SJ, O'Donnell RT, et al. Are radiometal-labeled antibodies better than Iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131, and yttrium-90-labeled Lym-1 antibody in patients with non-Hogkin's lymphoma. Clin Lymphoma 2000; 1: 118-126.
21. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294:1537-1540.
22. DeNardo SJ, Jungerman JA, DeNardo GL, et al. The choice of radionuclides for radioimmunotherapy. In: Thiessen JW, Paras P, eds. Developmental Role of Short-Lived Radionuclides in Nuclear Medicine Practice. Oak Ridge: Department of Energy Technical Information Center; 1982:401-404.
23. Wessels BW, Vessella RL, Palme DF, et al. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 1989; 17:1257-1263.
24. Srivastava SC. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother Radiopharm 1996; 11:43-50.
25. Shen S, DeNardo GL, Yuan A, et al. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med 1994; 35:1381-1389.
26. Siegel JA. Quantitative bremsstrahlung SPECT imaging: Attenuation-corrected activity determination. J Nucl Med 1994; 35:1213-1216.
27. Kennel SJ, Stabin M, Roeske JC, et al. Radiotoxicity of Bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res 1999; 151:244-256.
28. Kennel SJ, Chappell LL, Dadachova K, et al. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother Radiopharm 2000; 15:235-244.
29. 213Bi-an α-particle emitter. Nucl Med Biol 1998; 25:241-246.
30. Jurcic JG, McDevitt MR, Sgouros G, et al. Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213-HuM195 (anti-CD33). Proc Am Soc Clin Oncol 1999; 18:7a (Abstract #22).
31. Kennel SJ, Brechbiel MW, Milenic DE, et al. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49. Cancer Biother Radiopharm 2002; 17:219-231.
32. Bodei L, Kassis AI, Adelstein SJ, et al. Radionuclide therapy with iodine-125 and other Auger-electron-emitting radionuclides: Experimental models and clinical applications. Cancer Biother Radiopharm 2003; 18:861-877.
33. 111In-labeled epidermal growth factor administered to atyhmic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 2003; 44:1469-1479.
34. 125I in mammalian cells. Radiat Res 1987; 111:305-318.
35. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998; 25:1341-1351.
36. Kassis AI. Invited Commentary: Cancer therapy with Auger electrons: Are we almost there? J Nucl Med 2003; 44:1479-1480.
37. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994; 35:152-156.
38. 111In-21T-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med 2000; 41:952-958.
39. Vaidyanathan G, Affleck DJ, Zalutsky MR. Method for radioiodination of proteins using N-succinimidyl 3-Hydroxy-4-iodobenzoate. Bioconjug Chem 1997; 8:724-729.
40. DeNardo GL, Kroger LA, DeNardo SJ, et al. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994; 73:1012-1022.
41. 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 2003; 44:77-84.
42. DeNardo GL, Mirick GR, Kroger LA, et al. Antibody responses to macrocycles in lymphoma. J Nucl Med 1996; 37:451-456.
43. Kukis DL, DeNardo SJ, DeNardo GL, et al. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med 1998; 39:2105-2110.
44. Kukis DL, DeNardo GL, DeNardo SJ, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 21T-BAT-Lym-1 immunoconjugates. Cancer Res 1995; 55:878-884.
45. Paik CH, Hong JJ, Ebbert MA, et al. Relative reactivity of DTPA, immunoreactive antibody-DTPA conjugates, and nonimmunoreactive antibody-DTPA conjugates toward indium-111. J Nucl Med 1985; 26:482-487.
46. DeNardo G, Yuan A, Goldstein D, et al. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. Cancer Biother Radiopharm 2003; 18:231-237.
47. Siegel JA. Revised nuclear regulatory commission regulations for release of patients administered radioactive materials: Outpatient iodine-131 anti-B1 therapy. J Nucl Med 1998; 39(suppl):28S-33S.
48. 131I-anti-B1 antibody: Radiation exposure to family members. J Nucl Med 2001; 42:907-915.
49. 131I-tositumomab therapy. J Nucl Med 2002; 43:354-363.
50. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002; 43:267-272.
51. Wiseman GA, Leigh B, Witzig T, et al. Radiation exposure is very low to family members of patients treated with yttrium-90 Zevalin™ anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med 2001; 28:1198.
52. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
53. Stein R, Govindan SV, Mattes MJ, et al. Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 2003; 63:111-118.
54. Kaminski M, Zasadny K, Francis L, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14:1974-1991.
55. 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999; 5:3281s-3286s.
56. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2:457-470.
57. 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998; 13:239-254.
58. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence and design considerations in multiple dose (fractionated) radioimmunotherapy. Cancer 2002; 94:1332-1348.